華爾泰(001217.SZ):擬投建年產5萬噸環已胺和二環已胺項目
格隆匯2月9日丨華爾泰(001217.SZ)公佈,公司將以自籌資金18313.2萬元建設年產5萬噸環已胺和二環已胺項目,延長公司基礎化工產品延鏈,優化產品結構,加快企業發展步伐。
食品甜味劑環已基氨基磺酸鈉(甜蜜素)中國是全球第一生產大國,每年消耗約8萬噸環已胺。我國輪胎產量已是世界上輪胎第一大國,橡膠促進劑N:環已基-2-苯並噻唑次磺酰胺(CBS)需求增長,中國環已胺得到快速發展。
該項目涉及到的環已胺與二環已胺聯產後能在精餾成品時最大優化節省能源,並在反應過程中未反應完全的中間產物進行分類回收以降低裝置物料消耗。二環己胺是用途廣泛的精細化工中間體,主要用於合成橡膠促進劑、金屬緩蝕劑、表面活性劑、油田化學品、醫藥和農藥等領域,以其合成的精細化學品大多是有發展前景的新產品。
隨着該項目的實施,將進一步提高公司品牌的市場佔有率,增強市場競爭力和抗風險能力,有利於公司把握行業發展趨勢和市場機遇,實現公司生產規模化、精益化,增強公司核心競爭力和持續盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.